Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 3/20 | 0.74 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.74 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.55 |
| ▸ | FPR2 | P25090 | 1/20 | 0.53 |
| ▸ | PLAAT3 | P53816 | 2/20 | 0.52 |
| ▸ | PLAAT5 | Q96KN8 | 2/20 | 0.52 |
| ▸ | PLAAT2 | Q9NWW9 | 2/20 | 0.52 |
| ▸ | PLAAT4 | Q9UL19 | 2/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | TACR1 | P25103 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8747064 | 0.89 | CHRM5 (0.79) | CHRM5CHRM3CHRM1NPC1GAA | |
| SCHEMBL378738 | 0.89 | TACR1 (0.58) | CHRM5CHRM3L3MBTL1SMN1; SMN2TACR1 | |
| SCHEMBL2470761 | 0.88 | ALDH1A1 (0.65) | CHRM5CHRM3NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5350274 | 0.88 | CHRM5 (0.77) | CHRM5CHRM3CHRM1NPC1GAA | |
| SCHEMBL378386 | 0.84 | TACR1 (0.57) | CHRM5CHRM3NPC1RAB9APLAAT3 | |
| SCHEMBL378422 | 0.82 | TACR1 (0.56) | CHRM5CHRM3NPC1GAARAB9A | |
| SCHEMBL2471145 | 0.81 | CHRM5 (0.77) | CHRM5CHRM3CHRM1SMN1; SMN2ALDH1A1 | |
| SCHEMBL3915618 | 0.81 | SMN1; SMN2 (0.56) | CHRM5CHRM3NPC1GAARAB9A | |
| SCHEMBL13593900 | 0.80 | CHRM5 (0.74) | CHRM5CHRM3CHRM1PLAAT3PLAAT5 | |
| SCHEMBL2473234 | 0.80 | CHRM5 (0.70) | CHRM5CHRM3CHRM1GAAFPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2371366-A1 | Heterocyclo inhibitors of potassium channel function | Bristol-Myers Squibb Company (US) | 2011-10-05 | — | — | EP | disclosed |
| US-20090312307-A1 | HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY | 2009-12-17 | — | — | US | disclosed |
| US-20090312307-A1 | HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY | 2009-12-17 | — | — | US | disclosed |
| US-7582654-B2 | Heterocyclo inhibitors of potassium channel function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-01 | — | — | US | disclosed |
| US-7582654-B2 | Heterocyclo inhibitors of potassium channel function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312307-A1 | HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION | KCNJ2, KCNH2, KCNQ5 | CHRM5 676/4885CHRM3 1015/4885CHRM1 1953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.